Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Winter;5(1):46-8.

Alendronate-Related Femoral Fracture in a premenopausal glucocorticoid treated patient

Maryam Mobini
Case Reports

Alendronate-Related Femoral Fracture in a premenopausal glucocorticoid treated patient

Maryam Mobini. Caspian J Intern Med. 2014 Winter.

Abstract

Background: Alendronate is a bisphosphonate that is approved to reduce bone loss in glucocorticoid treated patients. In this paper, we present a case of femoral fracture following the use of Alendronate.

Case presentation: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendronate 70 mg/week for 3 years. Despite improvement of bone density, she experienced a low truama femoral shaft fracture.

Conclusion: This case shows a rare complication of treatment by alendronate. It may be needed to evaluate patients with long term usage of bisphosphonates for cortical thickness.

Keywords: Alendronate; Bisphosphonate; Fracture; Hemolytic anemia; Prednisolon.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Radiography demonstrating a right femoral shaft fracture with displacement and cortical thickness
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lane NE. Metabolic bone disease. In: Firestein GS, Budd RC, Harris ED, McInnes IB, Ruddy Sh, Sergent JS, editors. Kelley's text book of rheumatology. 18th ed. Philadelphia: Saunders Elsevier; 2009. p. 1590.
    1. Iwamoto J, Takeda T, Sato Y. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin. 2006;22:919–28. - PubMed
    1. McClung M, Harris ST, Miller PD, et al. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. Am J Med. 2013;126:13–20. - PubMed
    1. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br. 2007;89:349–353. - PubMed
    1. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury. 2008;39:224–31. - PubMed

Publication types

LinkOut - more resources